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S172 Oral Presentationsin HSCs and CMPs. A rise in BCR-ABL levels in GMP populations
signified impending relapse. Post-SCTpatients harboredmore resid-
ual CML cells in CD34+ subpopulations than TKI-treated patients.
Our findings suggest that in patients with persistent MRD-positivity
post-SCT, the graft-versus-leukemia (GVL) effect may eliminate
mature leukemic CD34+ subpopulations in vivo more readily. Prim-
itive leukemic HSCs and CMPs, although persistent, are presumably
constrained by GVL in patients who do not fulfill criteria for relapse.
Conversely, TKI reduces the number of BCR-ABL-positive GMPs
and CMPs more efficiently. Our data support adjuvant TKI-treat-
ment for CML relapse post-SCT, and concurrent vaccination strate-
gies which can target surface proteins on HSCs to eradicate CML.HEMATOPOIESIS/MESENCHYMAL CELLS47
TIE2 + BONE MARROW ENDOTHELIAL CELLS REGULATE HEMATOPOI-
ETIC RECONSTITUTION IN VIVO
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Radiation and chemotherapy cause myelosuppression in patients
via damage to bone marrow (BM) hematopoietic stem/progenitor
cells (HSCs). HSCs reside adjacent to BM sinusoidal vessels but
the function of BM endothelial cells (BM ECs) in regulating HSC
fate in vivo remains less well understood. We hypothesized that
BM ECs are critical in regulating BM hematopoietic reconstitution
following radiation stress. To test this hypothesis, we used Cre-
LoxP recombination to create targeted deletion of the pro-apoptotic
genes, Bak and Bax, in Tie2 + BM ECs (Tie2Cre;Bak-/-;BaxFl/-
mice) andmeasured hematopoietic response to total body irradiation
(TBI). Tie2Cre;Bak-/-;BaxFl/- mice were compared with Tie2Cre;
Bak-/-; BaxFl/+ mice which have constitutive Bak deletion but retain
Bax in Tie2 + BM ECs. After exposure to 100 cGy TBI, Tie2Cre;
Bak-/-;BaxFl/- mice displayed a 2-fold increase in total viable
BM cells (p5 0.04), 4-fold increase in BM ckit+sca+lineage- (KSL)
progenitor cells (p\0.0001), 3-fold increase in colony-forming
unit-spleen day 12 content (p5 0.0003) and a 2-fold increase in 12-
week competitive repopulating units (CRUs) (p5 0.002) compared
to Tie2Cre;Bak-/-;BaxFl/+ mice. Comparable radioprotection
was observed after 300 cGy TBI. Since Tie2 is expressed by BM
ECs and a subset of BM HSCs, we wanted to determine whether
the radioprotection we observed in Tie2Cre;Bak-/-;BaxFl/- mice
was caused autonomously by protection of Tie2 + BM ECs or
Tie2 +HSCs. We transplanted 4  106 BM cells from Tie2Cre;
Bak-/-;BaxFl/- mice into lethally irradiated (950 cGy) wild type
B6.SJL mice such that the recipient mice were chimeric for Bak and
Bax deletions only in hematopoietic cells while retaining a wild
type BM microenvironment, verified by qRTPCR. At 16 weeks
post-transplant, the chimeric recipient mice were then exposed to
100 and 300 cGy TBI and we compared the hematopoietic response
of these mice to that of Tie2Cre;Bak-/-;BaxFl/- mice. After 100 cGy
TBI, the hematopoietic response of the chimeric mice revealed a sig-
nificant reduction in total viable BM cells (1.3-fold), BM KSL cells
(7.4-fold) and 12-wk CRU weeks (1.6-fold, p5 0.008) compared to
100 cGy-irradiated Tie2creBak-/-;BaxFl/- mice. These results
demonstrate that Tie2 + BM ECs positively regulate hematopoietic
reconstitution following injury and indicate that BMECs are a novel
mechanistic target for therapies to augment hematopoietic recovery
in patients undergoing radiation and/or chemotherapy.HISTOCOMPATIBILITY/ALTERNATIVE STEM
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PATIENT ETHNICITY MARKEDLY AFFECTS THE PROBABILITY OF FIND-
ING AN HLA-A, -B, -C, AND DRB1 ALLELE MATCHED UNRELATED DONOR
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The adult unrelated volunteer registries includemore then 14mil-
lion donors worldwide; however, the required precision of patient
and donor matching for high resolution HLA determinants, and
the ethnic variation of the patient population put a yet unknown con-
straint to the probability of finding a suitable donor. We evaluated
the results of unrelated searches for 398 consecutive patients.
Patients and donors were typed by HLA sequencing. Searches
were assisted by NMDP histocompatibility specialists for patients
to identify an HLA-A, B, C, DRB1 match (8/8) or a partial match
(7/8). HLA-DQB1 was considered in the search, but was not evalu-
ated in this analysis. For the purpose of this study, the search was
completed when confirmatory typing on a freshly drawn donor sam-
ple identified the first suitable donor. Such a donor was found for 336
(85%) patients after a median of 20 [95% C.I. 11-59] days: this was
an 8/8match for 209 (53%) patients and a 7/8 for 127 (32%) patients,
with no difference in search duration observed by matching grade.
With a 7/8, the mismatch was at -A (35%), -B (26%), -C (28%), or
-DRB1 (11%). The probability of finding a donor was not affected
by patient age or diagnosis, but was affected by the patient ethnicity.
An 8/8match was found for 181/293 (62%)Caucasians, 22/65 (34%)
Hispanics, and 6/40 (15%) African-Americans, and a 7/8 match was
found for 80 (27%) Caucasians, 28 (43%) Hispanics and 19 (48%)
African-Americans (p\0.0001). Therefore, only 11% of Caucasians
had no suitable donor compared to 23% of Hispanics and 37% of
African Americans.
Consistent with overall NMDP data, among those with a suitable
match, 161/336 (48%) patients reached transplantation after a
median of 101 [95% C.I.; 56-258] days from the search inception.
The interval from finding the first donor to transplant was a median
of 81 [95% C.I.: 45-199] days, about 4-fold longer than the search
itself. Reaching transplant was affected by the match grade, 107/
209 (51%) for 8/8, 54/127 (43%) for 7/8, and 3/62 (5%) for those
without a match (p\0.0001). The low probability of reaching trans-
plant despite a suitable donor is alarming: 40% deteriorated or died,
17% received other treatment modalities, 14% declined or failed to
make a decision, 14% waited for a better match, 16% other reasons.
A suitablymatched unrelated donor is available for the largemajority
of the patients, however, Hispanic or African-American ethnicity
represents a barrier to find a suitable donor.49
CAN HISTOCHECK ALGORITHM PREDICT HIGH-RISK HLA ALLELE MIS-
MATCH COMBINATIONS RESPONSIBLE FOR SEVERE ACUTE GRAFT-VER-
SUS-HOST DISEASE?
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HLA polymorphism remains a major hurdle for hematopoietic
stem cell transplantation (HSCT). In 2004 Elsner et al (BMT) pro-
posed the ‘‘HistoCheck’’ web-based tool to estimate the allogeneic
potential between HLA-mismatched stem cell recipient/donor pairs
expressed as a matching score (dissimilarity score, DSS). DSS is
based on the structural data of HLA molecules and the functional
similarity of amino acids. A high DSS score represents high dissim-
ilarity between MHC molecules.
Objective:We sought to investigate the potential of DSS to predict
high-risk HLA allele mismatch combinations responsible for severe
acute graft-versus-host disease (aGvHDgrades III and IV) from data
recently published by Kawase et al, Blood, 2007 by comparing DSS
in low and high risk combinations.
Method:DSS were calculated for 110 HLA allele mismatch combi-
nations observed in 3830 donor/recipient pairs using the Histo-
Check tool available on the Web (WWW.histocheck.org). We
compared ranges and means of DSS among high risk versus low
risk allele combinations.
Results: An example of a higher risk combination is Cw*0303 (do-
nor) – 1502 (patient) that was observed in 25 pairs with HR of
3.22 (p\0.001). A lower risk combination containing the same re-
cipient allele but a different donor option is Cw*0801 – 1502 (ob-
served in 36 pairs) with HR of 1.59 (p5 0.19). DSS for these 2
